Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
Marinus Pharmaceuticals, Inc. (MRNS) will release its financial results for Q4 and full year 2023 on March 5, 2024, followed by a conference call. The company focuses on developing therapeutics for seizure disorders.
02/20/2024 - 07:00 AM
RADNOR, Pa. --(BUSINESS WIRE)--
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on March 5, 2024. The Company will host a conference call at 4:30 p.m. E.T. on March 5, 2024, to provide a business update and discuss financial results.
Tuesday, March 5, 4:30 p.m. E.T.
Domestic: (888) 550-5280
https://events.q4inc.com/attendee/513453609
An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/events-and-presentations .
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit www.marinuspharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220631175/en/
Company Contacts
jdenike@marinuspharma.com
Media
mcameron@marinuspharma.com
Source: Marinus Pharmaceuticals
When will Marinus Pharmaceuticals release its financial results for Q4 and full year 2023?
Marinus Pharmaceuticals will release its financial results for Q4 and full year 2023 on March 5, 2024.
What time will the conference call to discuss financial results be held on March 5, 2024?
The conference call to discuss financial results will be held at 4:30 p.m. E.T. on March 5, 2024.
What is the focus area of Marinus Pharmaceuticals?
Marinus Pharmaceuticals is dedicated to developing innovative therapeutics to treat seizure disorders.
Marinus Pharmaceuticals Inc
MRNS Rankings
#1099 Ranked by Stock Gains
MRNS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
About MRNS
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
